Year: 2024

– Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts– Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS– Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed– Inupadenant deprioritized to focus resources on other programs WATERTOWN, Mass. and GOSSELIES, Belgium, Dec. 12, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced...

CAMARILLO, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) — Sacks Parente Golf, Inc. (NASDAQ: SPGC) (the “Company”), a technology-forward golf company with a growing portfolio of golf products, including putters, golf shafts, golf grips, and other golf-related accessories, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.4 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering consists of 7,000,000 Common Units (or Pre-Funded Units), each consisting of one (1) share of Common Stock or one (1) Pre-Funded Warrant to purchase one (1) share of Common Stock, one (1) Series A Common Warrant to purchase one (1) share of Common Stock per warrant, and one (1) Series B Common Warrant to purchase...

Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction from Ozempic® therapy in chronic kidney disease-related events, including persistent ≥50% decline in estimated glomerular filtration rate (eGFR), onset of persistent eGFR 300 and

AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right (“CVR”) for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events relating to the level of annual global net revenue of LUM-201 up to the year 2037, different transactions involving Lumos Pharma or its assets...

WILMINGTON, Del., Dec. 12, 2024 (GLOBE NEWSWIRE) — Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) (the “Company” or “Onfolio”), a company that acquires and manages a diversified portfolio of online businesses, today announced that it has successfully completed the sale of its BWPS WordPress business for $780,000 to WebStreet, a micro private equity investment fund in an all-cash deal, with $650,000 cash released immediately and $130,000 held back pending final completion of migration. The Company expects to record a capital gain of approximately $150,000 from the sale. For the fiscal year ended 12/31/2023, the BWPS WordPress business generated approximately $360,000 in revenue and $200,000 in unaudited adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”). “We decided...

HALIFAX, Nova Scotia, Dec. 12, 2024 (GLOBE NEWSWIRE) — Morien Resources Corp. (“Morien” or the “Company“) (TSX-V:MOX) is pleased to provide the following corporate and project update to its shareholders and investors. Donkin Coal Mine Since the Donkin Coal Mine’s (“Donkin” or the “Mine”) idling during the fourth quarter of 2023, Morien has taken an active role in advocating and assisting in numerous initiatives to reopen the Mine. These initiatives have targeted the broader public, government officials and local politicians. Morien continues to work diligently to advocate for a potential return to production and will provide further updates to its shareholders and investors as to the status of operations at the Mine as they become available. The Company is of the opinion that any potential return to production...

DOE awards contract to LIS Technologies (Laser Isotope Separation Technologies) as a prime contractor and NANO Nuclear Energy as a key subcontractor under which they may access task orders with a minimum value of $2 million each as the companies seek to progress their nuclear fuel production, enrichment and related technologies and capabilities  New York, N.Y., Dec. 12, 2024 (GLOBE NEWSWIRE) — LIS Technologies Inc. (“LIST”) and its subcontractor NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear”) are proud to announce their selection by the U.S. Department of Energy (DOE) to participate as one of six contract awardees in DOE’s Low-Enriched Uranium (LEU) Enrichment Acquisition Program. This milestone achievement is an outgrowth of the existing investment and collaboration relationship between LIST and NANO Nuclear announced...

Mr. Natan Israeli served for three decades in the Israeli Air Force as a senior officer and will support ParaZero’s growing activity in the military and defense markets Tel Aviv, Israel, Dec. 12, 2024 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “Company” or “ParaZero”), an aerospace company focused on safety systems for defense and commercial drones and urban air mobility aircraft, today announces it has strengthened its board of directors with the appointment of Mr. Natan Israeli, a Brig. Gen. (Res.), formerly Head of the Personnel Directorate in the Israeli Air Force (IAF) and leader of a UAV squadron, effective December 11, 2024. Mr. Israeli has served as Kaltura Inc.’s Chief Customer Officer since November 2020 and as an executive officer since January 2024. Prior to joining Kaltura, throughout 2020...

MANITOWOC, Wis., Dec. 12, 2024 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations, and maintenance service solutions, announced today its selection for a three-year contract by a longstanding, nationwide Energy Service Company (ESCO) partner. This new contract and expanded relationship will commence in January 2025 and is anticipated to generate $5 – $10 million per year. Orion has been named one of three approved suppliers for turnkey lighting projects across the ESCO’s extensive customer network. Under the agreement, Orion’s comprehensive services will include site visits, detailed lighting audits, fixture manufacturing, project management, fixture installation, and the installation and commissioning of its industry-leading...

HONG KONG, Dec. 12, 2024 (GLOBE NEWSWIRE) — PS International Group Ltd.(NASDAQ: PSIG) (“PSIG” or the “Company”), a long-established global logistics service provider headquartered in Hong Kong specializes in cross-border air freight services, today announced its unaudited financial results for the six months ended June 30, 2024. The unaudited financial results presented in this announcement pertain to PSI Group Holdings Ltd and its subsidiaries, rather than PS International Group Ltd., as the business combination had not yet been completed until July 18, 2024. Financial Summary for the Six Months Ended June 30, 2024 (all results compared to the six months ended June 30, 2023, unless otherwise noted)Revenues were $39.4 million, a decrease of 41.3%. Gross profit were $1.2 million, a decrease of 84.2%. Net loss was $0.4 million,...